News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
News Teva plans migraine drug filing later this year Blockbuster hopeful could launch next year if approved.
News AZ sells migraine drug rights to Grunenthal for $300m AZ says migraine outside its strategic focus.
News Brain infection would be bad news for Roche's MS drug Ocrevu... Suggestion is that PML case was caused by previous treatment.
News Merck tries again in Alzheimer's with Teijin's tau antibody Target is implicated in a number of nervous system diseases.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.